ANDA 204227, held by Sandoz. Gatifloxacin.
As of Nov 16, 2026, ANDA 204227 (Gatifloxacin), held by Sandoz, was first approved by FDA on Jul 11, 2016, with 1 approved supplement and 0 published complete response letters.
Gatifloxacin ophthalmic solution 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 11, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Gatifloxacin0.5% · solution/drops;ophthalmic | Gatifloxacin | Rx |
| Dec 23, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 11, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters